small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
  1. Capabilities

Medical Devices

  • PDFPDF
    • Email
    • LinkedIn
    • Facebook
    • Twitter
    Share this page
  • Overview
  • Experience

Key Contacts

Charles B. KleinT. Reed StephensNimalka Wickramasekera
View Our Full Team

Resources

Product Liability & Mass Torts Digest

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.

Key Contacts

Charles B. KleinT. Reed StephensNimalka Wickramasekera
View Our Full Team

Areas of Focus

With more than 100 attorneys, our IP Practice is one of the most active and highly regarded in the U.S. In this legal discipline, very few firms offer as wide a spectrum as that of our life sciences and technology experience. Technologies Covered by Our Practice

  • Mechanical & Systems Engineering – products and devices designed to carry out specific functions, manufacturing, or process steps (e.g., medical devices, heat transfer, fluid control, and industrial process equipment)
  • Life Sciences & Biotechnology – genetically engineered and DNA-based technology; implantable devices; diagnostics, vaccines, probes, vectors, and cell lines; and related discoveries for application in compositions, treatments, and therapeutics
  • Electrical Engineering & Electronics― computer hardware, peripherals, and software; artificial intelligence; and digital devices

Our Health Care & Life Sciences Industry Group stands ready to meet our clients wherever they may be in the product development life cycle—research, commercialization, or distribution—to provide advice and practical solutions to clients, whatever the complexity of the need. We routinely draw from our extensive business and regulatory knowledge to help sector participants navigate the complete product life cycle, including:

  • clinical research and development programs, including HIPAA privacy and consent;
  • sales and marketing compliance, including employee training on fraud and abuse and Code of Ethics;
  • marketing application strategies for drugs, biologics, and medical devices and U.S. state licensing requirements;
  • government Price Reporting obligations for Medicare, Medicaid, the Department of Veterans Affairs, and 340B;
  • the negotiation of customer and distributor supply agreements for both pharmaceutical manufacturers and medical device companies, including government purchasers under the Federal Supply Schedule (FSS);
  • design and execution of Patient Access programs (e.g., kickstart, patient assistance and co-pay assistance programs for pharmaceutical manufacturers, limited pharmacy distribution networks, and hub service vendors); and
  • international trade compliance, including country of origin.

We have extensive experience advising clients on risk management concerns involving mergers and acquisitions, public policy, IP protection, and an array of regulatory compliance matters relating to product marketing, foreign bribery, and import/export controls.

With former DOJ attorneys and in-house attorneys embedded in our Health Care & Life Sciences Industry Group, our attorneys have extensive experience in matters involving state and federal government law enforcement and investigations, including federal False Claims Act (FCA) defense, internal investigations, fraud and abuse compliance training, congressional investigations, and health care litigation.

Related Capabilities

Commercial Litigation & Disputes
Employee Benefits & Executive Compensation
Environmental
Government Program Fraud, False Claims Act & Qui Tam Litigation
Intellectual Property
International Trade
Labor & Employment
Litigation/Trials
Mergers & Acquisitions
Patent Litigation
Private Equity
Privacy & Data Security
Trade Secrets, Non Competes & Restrictive Covenants
Health Care
Life Sciences

Recent Experience

Court Square Capital Partners in its Definitive Agreement to Sell Advanced Diabetes Supply Group for US$1.1B
Docter Inc. and Aimfinity Investment Corp. I Announce Definitive Merger Agreement
Picard Medical and its Subsidiary, SynCardia Systems, Announce Business Combination with Altitude Acquisition Corp.
Culper Capital Partners's Acquisition of Ring Precision Components, New Vision Industries, and Dieco to form The Producto Group
Surgical Science Sweden AB's Acquisition of Simbionix
Incodema Holdings' Acquisition of Dahlquist Machine
Hospice Source's Acquisition of Superior Healthcare Inc.
United American Healthcare Corp. Sale of Pulse Systems LLC to Heraeus Holding GmbH
Won Rare Denial of Class Certification for Medtronic in Securities Fraud Litigation

Resources

Product Liability & Mass Torts Digest

Notable

50+ attorneys with technical degrees

Ranked in Product Liability, Mass Tort, and Class Action – Defense: Pharmaceuticals and Medical Devices

The Legal 500 US 2023

50+ attorneys with technical degrees

The Legal 500 US 2023

Ranked in Product Liability, Mass Tort, and Class Action – Defense: Pharmaceuticals and Medical Devices

ResourceSurvey of State Transaction Notification Requirements
This survey provides a comprehensive overview of Baby HSR laws throughout the United States, identifying which states have adopted premerger notification requirements and summarizing key details such as the types of transactions covered, the content of required notices, and the timing of the review. 
Learn More
ResourceSurvey of State Transaction Notification Requirements
This survey provides a comprehensive overview of Baby HSR laws throughout the United States, identifying which states have adopted premerger notification requirements and summarizing key details such as the types of transactions covered, the content of required notices, and the timing of the review. 
Learn More

Related Insights & News

View All Insights & News
Speaking Engagement
Partners Imad Khan and Keerthika Subramanian Discuss Hot Topics in International Arbitration and Strategic Transactions in India as Part of Practising Law Institute Program

May 9, 2025

Client Alert
White House Memorandum Elaborates on Prior Executive Order with Requirements for “High-Impact AI” Used by Federal Agencies

May 2, 2025

Sponsorship
Winston & Strawn Sponsors Healthcare Business International 2025

March 24, 2025

Client Alert
Executive Order Reemphasizes Healthcare Price Transparency

March 4, 2025

Speaking Engagement
Banee Pachuca to Teach Fraud and Abuse Course at the University of Houston Law Center

Spring 2025

Blog

New Theory for Establishing Causation Under California’s Learned Intermediary Doctrine (Himes v. Somatics)

July 2, 2024

Recognitions
Winston & Strawn Recognized in The Legal 500 U.S. 2024

June 12, 2024

Blog
Eleventh Circuit Affirms CoolSculpting Device Manufacturer Win on Warning and Defect Claims

August 11, 2023

Speaking Engagement
Ivan Poullaos Discusses How the Supreme Court’s Enablement Ruling in Amgen v. Sanofi Will Affect Biologic Patent Portfolio Strategies

June 27-28, 2023

Client Alert
Clarifying the Enabling Obligation of the Patent Act: Amgen Inc. v. Sanofi

June 21, 2023

Seminar/CLE
Winston & Strawn’s Product & Mass Torts Summit 2023

June 14, 2023

Blog
The FTC Attempts (Again) to Lay the Groundwork for Use of Its Penalty Offense Authority: This Time for Deceptive Product Claims

May 8, 2023

Speaking Engagement
Partners Imad Khan and Keerthika Subramanian Discuss Hot Topics in International Arbitration and Strategic Transactions in India as Part of Practising Law Institute Program
May 9, 2025
Client Alert
White House Memorandum Elaborates on Prior Executive Order with Requirements for “High-Impact AI” Used by Federal Agencies
May 2, 2025
Sponsorship
Winston & Strawn Sponsors Healthcare Business International 2025
March 24, 2025
Client Alert
Executive Order Reemphasizes Healthcare Price Transparency
March 4, 2025
Speaking Engagement
Banee Pachuca to Teach Fraud and Abuse Course at the University of Houston Law Center
Spring 2025
Blog

New Theory for Establishing Causation Under California’s Learned Intermediary Doctrine (Himes v. Somatics)

July 2, 2024
Recognitions
Winston & Strawn Recognized in The Legal 500 U.S. 2024
June 12, 2024
Blog
Eleventh Circuit Affirms CoolSculpting Device Manufacturer Win on Warning and Defect Claims
August 11, 2023
Speaking Engagement
Ivan Poullaos Discusses How the Supreme Court’s Enablement Ruling in Amgen v. Sanofi Will Affect Biologic Patent Portfolio Strategies
June 27-28, 2023
Client Alert
Clarifying the Enabling Obligation of the Patent Act: Amgen Inc. v. Sanofi
June 21, 2023
Seminar/CLE
Winston & Strawn’s Product & Mass Torts Summit 2023
June 14, 2023
Blog
The FTC Attempts (Again) to Lay the Groundwork for Use of Its Penalty Offense Authority: This Time for Deceptive Product Claims
May 8, 2023
View All Insights & News
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising